Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,310 public trials 520 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

NCT04150497

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +19 more
Locations
  • University of California, Los Angeles (UCLA) - Medical Center Los Angeles, California, United States
  • University of Colorado - Aurora Cancer Center Aurora, Colorado, United States
  • Sarah Cannon - Colorado Blood Cancer Institute Denver, Colorado, United States
  • University of Chicago Chicago, Illinois, United States
View all 19 locations
View Trial Details
Recruiting

Vyxeos® With Clofarabine for Pediatric AML

NCT07156435

Conditions
Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, +3 more
Locations
  • St. Anna Kinderspital Vienna, Austria
  • Rigshospitalet Copenhagen, Denmark
  • Universitätsklinikum Augsburg Augsburg, Germany
  • Charité Berlin Berlin, Germany
View all 13 locations
View Trial Details
Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03850574

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myelomonocytic Leukemia, +16 more
Locations
  • The Kirklin Clinic of UAB Hospital Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Irvine Irvine, California, United States
  • UCSD Moores Cancer Center La Jolla, California, United States
View all 34 locations
View Trial Details
Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420

Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL), Disease Attributes, Hemic and Lymphatic Diseases, +12 more
Locations
  • The University of Chicago Medical Center (UCMC) Chicago, Illinois, United States
  • Harvard Medical School - Massachusetts General Hospital Boston, Massachusetts, United States
  • Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick New Brunswick, New Jersey, United States
  • Sarah Cannon - St. David South Austin Medical Center Austin, Texas, United States
View Trial Details
Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

NCT05798897

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Disease, +18 more
Locations
  • City of Hope Duarte, California, United States
  • University of Colorado Aurora, Colorado, United States
  • Colorado Blood Cancer Institute (Sarah Cannon) Denver, Colorado, United States
  • University of Kansas Medical Center Kansas City, Kansas, United States
View Trial Details
Recruiting

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

NCT07126236

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Hospital Universitario Miguel Servet Zaragoza, Aragon, Spain
  • Hospital Universitario de Burgos Burgos, Castille and León, Spain
  • ICO Badalona Badalona, Catalonia, Spain
  • Hospital Universitari Vall d'Hebrón Barcelona, Catalonia, Spain
View all 15 locations
View Trial Details
Recruiting

Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

NCT05565807

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Beijing Chao-Yang Hospital，Capital Medicine University Beijing, Beijing Municipality, China
  • Peking university Third hospital Beijing, Beijing Municipality, China
  • The first affiliated hospital ,Sun Yat-sen University Guangzhou, Guangdong, China
  • The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou, Zhejiang, China
View Trial Details

Related conditions